Alliances

Found 54,375 articles

• Medinol Partners with CoSo Health to Launch the EluNIR™ Drug-Eluting Stent in the U.S.

  5/30/2023

  CoSo Health today announced signing a U.S. distribution agreement with Medinol for EluNIR™, a new generation, thin-strut drug-eluting stent (DES).

• XtalPi Announces Collaboration with Lilly, Using AI + Robotics to Uncover First-in-class Therapeutics

  5/30/2023

  Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company.

• Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

  5/30/2023

  Sun Pharmaceutical Industries Limited and Philogen S.p.A announced that they have entered into a licensing agreement for commercializing Philogen’s specialty product, Nidlegy™ in the territories of Europe, Australia and New Zealand.

• Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - May 30, 2023

  5/30/2023

  Morphogenesis, Inc. and CohBar, Inc. today announced that Morphogenesis' abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

• Synapse Medicine and CompuGroup Medical Announce Partnership to Revolutionize Prescribing and Clinical Decision Support

  5/25/2023

  Synapse Medicine, the leader in medication success, and CompuGroup Medical, the leader in software for providers, have announced a partnership to accelerate innovation in prescribing and allow physicians to benefit from time-saving technological advances in clinical decision support.

• Genome Medical Supporting Beam Therapeutics on its Sickle Cell Disease Clinical Trial

  5/25/2023

  Genome Medical, the leading telehealth provider of genetic services and solutions, is teaming up with Beam Therapeutics Inc. to provide access to genetic counseling for participants in Beam's BEACON clinical trial evaluating BEAM-101 as a potential treatment for sickle cell disease (SCD).

• Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API Space

  5/25/2023

  Centrient Pharmaceuticals ("Centrient") and Ginkgo Bioworks (NYSE: DNA) today announced they are expanding their existing partnership aimed at broadening Centrient's portfolio of environmentally friendly active pharmaceutical ingredients (APIs), following the success of previous work together.

• HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease

  5/25/2023

  HanAll Biopharma Co., Ltd. (KRX: 009420.KS) and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620.KS) announced that they have entered into a co-development agreement with NurrOn Pharmaceuticals Inc., a Boston-based preclinical-stage biopharma.

• Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors

  5/25/2023

  Transgene and BioInvent International AB announce positive Phase Ia data on the oncolytic virus BT-001 for the treatment of solid tumors.

• Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology

  5/25/2023

  Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate -based therapies, announced that it has extended its second multi-year collaboration with Boehringer Ingelheim for an additional two years.

• 

  ElevateBio Takes Title of Largest 2023 Funding with $401M Series D

  5/24/2023

  The Massachusetts-based company has claimed the year’s largest fundraise so far and secured a powerhouse R&D partner in Novo Nordisk to develop gene editing medicines.

• Azenta Announces Collaboration with the Lupus Research Alliance to Support the Advancement of Lupus Research and Drug Discovery

  5/24/2023

  Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics to support the development of the patient registry component of the Lupus Nexus, which aims to advance and accelerate lupus research and drug discovery through information exchange capabilities.

• Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center

  5/24/2023

  Adaptive Phage Therapeutics is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.

• Minaris Regenerative Medicine Streamlining Contract Manufacturing with Veeva Vault Quality Suite Applications

  5/24/2023

  Veeva Systems (NYSE: VEEV) today announced that Minaris Regenerative Medicine selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations.

• Be The Match BioTherapies® To Provide Robust Cell Therapy Infrastructure to Support Garuda Therapeutics’ Potentially Ground-Breaking Off-The-Shelf Cell Therapies

  5/24/2023

  Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, announced a working partnership with Garuda Therapeutics, a company working to create off-the-shelf, durable blood stem cell-based cellular therapies.

• Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute

  5/24/2023

  Phio Pharmaceuticals Corp. today announced its clinical development partner, AgonOx, Inc, in collaboration with Providence Cancer Institute, has completed the site initiation visit and can commence with patient accrual.

• Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials

  5/24/2023

  Endo International plc (OTC: ENDPQ) announced today that its subsidiary Endo Ventures Limited has executed an agreement with MAIA Pharmaceuticals, Inc. to distribute bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial in the U.S. Endo will commercialize the FDA-approved product through its Par Sterile Products business and expects to begin shipping in summer 2023.

• ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

  5/24/2023

  ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio.

• Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe

  5/24/2023

  Alvotech and Advanz Pharma announced that the companies have entered into an exclusive partnership agreement regarding the supply and commercialization of five biosimilar candidates in Europe.

• Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor

  5/23/2023

  Pathos AI, Inc. (www.pathos.com) announced today that it has entered into a worldwide license agreement to develop FT-7051, a small molecule CBP/p300 inhibitor program from Novo Nordisk as Pathos’ first clinical-stage asset in its pipeline.